Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vantictumab · 2 trials · 3 indications
The maximum tolerated dose (MTD) will be determined in patients treated with vantictumab in combination with weekly nab-paclitaxel
| Arm | Type | Description |
|---|---|---|
| Docetaxel | EXPERIMENTAL | Drug: Docetaxel - administered intravenously |
| vantictumab | EXPERIMENTAL | Drug: vantictumab - administered intravenously |
| Vanctictumab (OMP-18R5) | EXPERIMENTAL | Vantictumab will be administered by intravenous (IV) infusion. |
| Nab-Paclitaxel | EXPERIMENTAL | Nab-Paclitaxel will be administered by intravenous (IV) infusion. |
| Gemcitabine | EXPERIMENTAL | Gemcitabine will be administered by intravenous (IV) infusion. |
| Name | Type | Description |
|---|---|---|
| Docetaxel | DRUG | Docetaxel will be administered IV. |
| vantictumab | DRUG | Vantictumab will be administered intravenously |
| Nab-Paclitaxel | DRUG | Nab-Paclitaxel will be administered by intravenous (IV) infusion. |
| Gemcitabine | DRUG | Gemcitabine will be administered by intravenous (IV) infusion. |
Inclusion Criteria: * Signed Informed Consent Form * Age ≥18 years * Histologically documented recurrent or advanced (Stage IV) NSCLC * Eastern CooperativeOncology Group (ECOG) performance status of 0 or 1 * All acute treatmentrelated toxicity from prior therapy must have resolved to Grade ≤ 1 prio...
Top 20 of 68 competitors
Vantictumab is an investigational drug being studied for the treatment of solid tumors and pancreatic cancer. It has been evaluated in clinical trials for previously treated non-small cell lung cancer and for previously untreated stage IV pancreatic cancer. The drug is in Phase 1 clinical development.
Vantictumab is being developed by Mereo BioPharma Group plc, a biopharmaceutical company. The company's stock is traded under the ticker symbol MREO. The drug is currently in Phase 1 clinical development for oncology indications.
Vantictumab is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials for the drug have been completed, and it is being studied for the treatment of solid tumors and pancreatic cancer.
Vantictumab has been studied in two completed Phase 1 clinical trials. One trial (NCT01957007) evaluated Vantictumab in combination with docetaxel in patients with previously treated non-small cell lung cancer. Another trial (NCT02005315) studied Vantictumab in combination with nab-paclitaxel and gemcitabine in previously untreated stage IV pancreatic cancer.
Yes, Vantictumab is also known as OMP-18R5. This alternative name appears in clinical trial records, such as the study of Vantictumab (OMP-18R5) in combination with docetaxel for previously treated non-small cell lung cancer. Both names refer to the same investigational drug.